Chemoinformaics analysis of (25R)-Spirosta-3,5-dien
| Molecular Weight | 396.615 | nRot | 0 |
| Heavy Atom Molecular Weight | 356.295 | nRig | 30 |
| Exact Molecular Weight | 396.303 | nRing | 6 |
| Solubility: LogS | -6.499 | nHRing | 2 |
| Solubility: LogP | 6.247 | No. of Aliphatic Rings | 6 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 69 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 29 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 2 |
| No. of Hydrogen atom | 40 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 27 | No. of Saturated Rings | 4 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 73.3657 |
| nHD | 0 | BPOL | 43.6003 |
| QED | 0.464 |
| Synth | 5.377 |
| Natural Product Likeliness | 3.486 |
| NR-PPAR-gamma | 0.004 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.997 |
| Pgp-sub | 0 |
| HIA | 0.005 |
| CACO-2 | -4.941 |
| MDCK | 0.0000311 |
| BBB | 0.51 |
| PPB | 0.987668 |
| VDSS | 1.822 |
| FU | 0.0139951 |
| CYP1A2-inh | 0.033 |
| CYP1A2-sub | 0.465 |
| CYP2c19-inh | 0.139 |
| CYP2c19-sub | 0.963 |
| CYP2c9-inh | 0.19 |
| CYP2c9-sub | 0.204 |
| CYP2d6-inh | 0.064 |
| CYP2d6-sub | 0.891 |
| CYP3a4-inh | 0.419 |
| CYP3a4-sub | 0.661 |
| CL | 23.334 |
| T12 | 0.032 |
| hERG | 0.964 |
| Ames | 0.034 |
| ROA | 0.203 |
| SkinSen | 0.969 |
| Carcinogencity | 0.074 |
| EI | 0.011 |
| Respiratory | 0.969 |
| NR-Aromatase | 0.486 |
| Antiviral | No |
| Prediction | 0.50758 |